ASCO24: The Era of the ADCs in NSCLC

ASCO24: The Era of the ADCs in NSCLC

Up next

Breast Cancer Highlights From ASCO26: OPTIMA, lidERA, and VIKTORIA-1

Dr. Megan Kruse and Dr. Hope Rugo discuss practice-changing data in metastatic breast cancer and critical shifts in the treatment of early-stage disease that were presented at the 2026 ASCO Annual Meeting. LINK TO FULL TRANSCRIPT 

GU Cancer Highlights From ASCO26: PROTEUS, TALAPRO-3, and RAMPART

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss high-impact abstracts in the treatment of prostate, bladder, and kidney cancers that were presented at the 2026 ASCO Annual Meeting. LINK TO FULL TRANSCRIPT 

Recommended Episodes

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2023.1 Part 2
ASCO Guidelines

Dr. Dwight Owen is back on the ASCO Guidelines podcast, discussing the latest updates to the ASCO living guidelines for stage IV NSCLC. In Part 2, Dr. Owen presents the update for stage IV NSCLC with driver alterations. He reviews new evidence from KRYSTAL-1, and reviews a new re ...  Show more

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2024.1
ASCO Guidelines

Dr. Jyoti Patel discusses the latest update to the stage IV NSCLC with driver alterations living guideline, specifically for patients with EGFR or ROS1 alterations. She shares the latest recommendations based on recently published evidence, such as the FLAURA2, MARIPOSA-2, and TR ...  Show more

Podcast 300: NADIM II trial offers “quite exciting” results in lung cancer
Clinical Conversations

A VIDEO RECORDING OF THIS INTERVIEW IS AVAILABLE HERE.

We’re back with another interview from this year’s IASLC conference.

This time, Christine Sadlowski and Dr. Julia Rotow interview Dr. Mar ...

  Show more

HER2 Testing in Breast Cancer: ASCO-CAP Guideline Update
ASCO Guidelines

Dr. Antonio Wolff and Dr. Kim Allison discuss the latest ASCO-CAP guideline update on HER2 testing in breast cancer. This guideline update affirms previous recommendations, and provides commentary based on data from the DESTINY-Breast04 trial. Dr. Wolff and Dr. Allison review the ...  Show more